WallStreetZenWallStreetZen

NASDAQ: EXAS
Exact Sciences Revenue

OverviewForecastEarningsRevenue
DividendOwnership
Exact Sciences revenue was $2.76B for the trailing 12 months ending Dec 31, 2024, with N/A growth year over year. Quarterly revenue for the quarter (Q4 2024) ending on Dec 31, 2024 was $713.4M, up 0.7% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, EXAS annual revenue was $2.8B, with 10.4% growth year-over-year.

EXAS past revenue growth

How has EXAS's revenue growth performed historically?

Company
10.37%
Industry
3.84%
Market
20.68%
EXAS's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
EXAS's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
EXAS's revenue growth is slowing... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

EXAS revenue history

Current Revenue
$2.8B
Current Earnings
-$1.0B
Current Profit Margin
-37.3%

Be the first to know when EXAS announces revenue.

EXAS Revenue History By Year

EXAS Yearly RevenueEXAS RevenueEXAS ChangeEXAS Revenue Growth
2024-12-31$2.76B$259.10M+10.37%
2023-12-31$2.50B$415.49M+19.93%
2022-12-31$2.08B$317.19M+17.95%
2021-12-31$1.77B$275.70M+18.49%
2020-12-31$1.49B$615.10M+70.19%
2019-12-31$876.29M$421.83M+92.82%
2018-12-31$454.46M$188.47M+70.86%
2017-12-31$265.99M$166.61M+167.66%
2016-12-31$99.38M$59.94M+151.99%
2015-12-31$39.44M$37.64M+2,093.38%
2014-12-31$1.80M-$2.35M-56.61%
2013-12-31$4.14M$0.000.00%
2012-12-31$4.14M-$19.00k-0.46%
2011-12-31$4.16M-$1.18M-22.10%
2010-12-31$5.34M$586.00k+12.32%
2009-12-31$4.76M$5.63M-648.79%
2008-12-31-$867.00k-$2.67M-148.22%
2007-12-31$1.80M-$2.95M-62.15%
2006-12-31$4.75M$500.00k+11.76%
2005-12-31$4.25M-$685.00k-13.88%
2004-12-31$4.94M$2.03M+70.11%
2003-12-31$2.90M$2.00M+223.41%
2002-12-31$897.00k$846.00k+1,658.82%
2001-12-31$51.00kN/AN/A
2000-12-31$0.00N/AN/A
1999-12-31$0.00N/AN/A
1998-12-31$0.00N/AN/A
1997-12-31$0.00N/AN/A

1 of 2

Exact Sciences Revenue FAQ

What was EXAS's revenue last quarter?

On Invalid Date, Exact Sciences (NASDAQ: EXAS) reported Q4 2024 revenue of $713.42 million up 10.29% year over year. In the same quarter last year, Exact Sciences's revenue was $646.89 million.

What was Exact Sciences's revenue in 2024?

Exact Sciences's annual revenue for the twelve months ending Dec 31, 2024 was $2.76 billion, a 10.37% increase year over year.

How much does Exact Sciences make in a day?

Based on Exact Sciences annual revenue for the past five years, EXAS makes an average of $5,808,980.82 per day.

What was Exact Sciences's annual revenue growth in the past year?

As of Q2 2025, Exact Sciences's revenue has grown 10.37% year over year. This is 6.53 percentage points higher than the US Diagnostics & Research industry revenue growth rate of 3.84%. Exact Sciences's revenue in the past year totaled $2.76 billion.

How much does Exact Sciences make in a year?

Exact Sciences's revenue by year for the past five years is:
  • Exact Sciences's revenue for the twelve months ending Dec 31, 2024 was $2.76 billion, a 10.37% increase year over year.
  • Exact Sciences's annual revenue for Dec 31, 2023 was $2.50 billion, a 19.93% increase from 2022.
  • Exact Sciences's annual revenue for 2022 was $2.08 billion, a 17.95% increase from 2021.
  • Exact Sciences's annual revenue for 2021 was $1.77 billion, a 18.49% increase from 2020.
  • Exact Sciences's annual revenue for 2020 was $1.49 billion, a 70.19% increase from 2019.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.